Letiția Elena Radu, Andra Beldiman, Ioana Ghiorghiu, Alina Oprescu, Constantin Arion and Anca Coliță
The international standard protocol for acute lymphoblastic leukaemia (ALL), the most common haemato-oncological pathology at paediatric age, uses anthracyclines as antitumor agents, potentially associated with early or late onset cardiac damage. Currently, echocardiography is the gold standard in the diagnosis of cardiotoxicity, but several biomarkers are evaluated as a possible replacement, pending more extensive clinical studies. We started a prospective study in order to determine the role of two biomarkers, troponin and heart-type fatty acid binding protein, in the evaluation of cardiotoxicity in children over one year of age, diagnosed with ALL. Between February 2015 and April 2016, 20 patients were enrolled and monitored at diagnosis, during chemotherapy and four months after the end of reinduction, through cardiac evaluation and dosing of those two markers in five different points of the treatment protocol. During the first year of follow-up, the patients did not develop clinical signs of cardiac damage, but the study showed a slight increase in troponin levels during chemotherapy, with the return to baseline value after treatment cessation, and also a correlation with the total dose of anthracyclines given to the patient. On the other hand, the second biomarker, heart-type fatty acid binding protein, did not seem to be useful in detecting subclinical cardiac damage in these patients.
Laurenţiu Lucaci, Ștefana Maria Moisă, Marin Burlea and Lucian Miron
. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acutelymphoblasticleukemia. Leukemia. 2010;24(2):345-54. DOI: 10.1038/leu.2009.251
12. Mitchell C, Richards S, Harrison CJ, Eden T. Long-term follow-up of the United Kingdom medical research council protocols for childhood acutelymphoblasticleukaemia, 1980-2001. Leukemia. 2010;24(2):406-18. DOI: 10.1038/leu.2009.256
13. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute
Iuliu C. Ivanov, Daniela Jitam, Georgiana E. Grigore, Mihaela Zlei, Anca V. Ivanov, Silvia Dumitraş, Eugen Carasevici and Ingritli C. Miron
1. De Braekeleer E, Douet-Guilbert N, Le Bris MJ, Basinko A, Morel F, De Braekeleer M. Gene expression profiling of adult t(4;11)(q21;q23)-associated acutelymphoblasticleukemia reveals a different signature from pediatric cases. Anticancer Res. 2012 Sep;32(9):3893-9
2. De Braekeleer M, Morel F, Le Bris MJ, Herry A, Douet-Guilbert N. The MLL gene and translocations involving chromosomal band 11q23 in acute leukemia. Anticancer Res. 2005 May-Jun;25(3B):1931-44
3. Drexler HG, Quentmeier H
outcome of children with acutelymphoblasticleukemia - experience of IIIrd Paediatric Clinic Timisoara. Rev Romana Med Lab. 2018;26(1):77-85. DOI: 10.1515/rrlm-2017-0029
16. Tripon F, Crauciuc GA, Moldovan VG, Bogliș A, Benedek IJ, Lázár E, et al. Simultaneous FLT3, NPM1 and DNMT3A mutations in adult patients with acute myeloid leukemia - case study. Rev Romana Med Lab. 2019;27(3):245-54. DOI: 10.2478/rrlm-2019-0022
17. Oltean A, Chincesan MI, Marginean O, Horvath E. Myelodysplastic syndrome with myelofibrosis in a 12-year-old patient - A case report. Rev
methylating/histone modifying enzymes: a potential link to childhood acutelymphoblasticleukemia, Int. J. Pediatr. Child Health, 2017, 5, 29-39.
Polito A. Polimeno R. Kanduc D. Peptide sharing between Parvovirus B19 and DNA methylating/histone modifying enzymes: a potential link to childhood acutelymphoblasticleukemia Int. J. Pediatr. Child Health 2017 5 29 39
 Kanduc, D., Epstein-Barr virus, immunodeficiency, and cancer: a potential crossreactivity connection. Intern. Med. Rev., 2018, 4, 1–17.
Kanduc D. Epstein-Barr virus
Aleksandra Pawlak, Bożena Obmińska-Mrukowicz, Iwona Zbyryt and Andrzej Rapak
1. Den Boer M.L., Harms D.O., Pieters R., Kazemier K.M., Gobel U., Körholz D., Graubner U., Haas R.J., Jorch N., Spaar H.J., Kaspers G.J., Kamps W.A., Van der Does-Van den Berg A., Van Wering E.R., Veerman A.J., Janka-Schaub G.E.: Patient stratification based on prednisolone-vincristineasparaginase resistance profiles in children with acutelymphoblasticleukemia. J Clin Oncol 2003, 21, 262-3268.
2. Escherich G., Tröger A., Göbel U., Graubner U., Pekrun A., Jorch N., Kaspers G., Zimmermann M., zur Stadt U., Kazemier
Andreea Oltean, Mihaela Ioana Chincesan, Oana Marginean and Emoke Horvath
lymphoblasticleukaemia: implications for disease biology. Leuk Res. 2006;30:233-239. DOI: 10.1016/j.leukres.2005.06.011
4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;1145(5):937-51. DOI: 10.1182/blood-2009-03-209262
5. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005;23(33):8520-30. DOI: 10.1200/JCO.2004